ABSTRACT: Membranous glomerulonephritis (MGN) is one of the most common causes of idiopathic nephrotic syndrome in adults. TLR4 gene polymorphisms have been reported to be associated with many inflammatory diseases. The objective of this study was to clarify the relationship between TLR4 gene polymorphisms and the pathogenesis of MGN. We recruited a cohort of 134 biopsy-diagnosed MGN patients and 263 healthy subjects that served as controls. Genotyping of TLR4 gene polymorphisms was performed using allele-specific polymerase chain reaction methods. We then analysed associations between TLR4 gene polymorphisms and clinical manifestations and pathogenesis of MGN. There was statistically significant difference of TLR4 gene rs10983755 A/G (p < 0.001) and rs1927914 A/G (p < 0.05) polymorphisms between controls and patients with MGN. The distributions of rs10759932 C/T and rs11536889 C/T polymorphisms were significantly different. A higher level of triglyceride was found in the non-GG group than in the GG group. The genotype of the non-AA group had a significantly higher ratio of proteinuria than that of the AA group. In addition, the distribution of haplotype frequencies of the TLR4 gene in 4 genetic variants revealed no statistical difference between normal patients and controls. The results demonstrated that patients with MGN have a different genotype distribution of the TLR4 gene from the normal controls. Our observations suggest that those polymorphisms contribute to the genetic background of MGN pathogenesis.
INTRODUCTION
Membranous glomerulonephritis (MGN) is a common primary or idiopathic nephropathy 1, 2 . MGN also appears as a disease secondary to other conditions (approximately 25%), mainly infections, neoplasms, and systemic lupus erythematosus (SLE) 3 . Although inflammatory cells are not usually detected, an inflammatory process is evident of trapping of immune complexes. Therefore, inflammation is highly related to this disease 4 . MGN may be a cause of chronic kidney disease and a final result of end-stage renal disease (ESRD) 5 . Taiwan has the highest prevalence of ESRD in the world and MGN may be one of the causes 4, 6, 7 . The study of inflammatory factors associated with MGN is helpful in elucidating and preventing of ESRD 8 . MGN is an immune complexes mediated disease as evidenced by the presence of immunoglobulins and complement components in capillary walls (subepithelial), and the morphological and immunopathological similarities between the experimental MGN and immunological glomerular diseases 9 . However, the aetiology and origin of the antigens that cause MGN remain unclear. The deposits may come from circulating immune complexes, form in situ, or come from foreign antigens previously deposited there 10 . Although MGN is a multi-factorial disease, an inflammatory pathway might play an important role in the pathogenesis of MGN 4, 9 .
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Toll-like receptors (TLRs), a key element of human innate immune response, up-regulate proinflammatory cytokines and co-stimulatory molecules as a first line host defence 11 . TLRs have been identified as key components of the pathogen-recognition process that mediates inflammatory responses 12 . TLR4 interacts with some ligands such as heat-shock proteins [13] [14] [15] , hyaluronan, fibronectin, fibrinogen, heparan lung surfactant protein-A 16 , and high mobility group box 1 17 . Polymorphisms of the TLR4 gene have been reported to be associated with many inflammatory diseases and the formation of cancers such as Crohn's disease 18 , ulcerative colitis 19 , and cervical cancer 20 . However, there are few reports about TLR4 in MGN 21, 22 . In this study, we investigated the association of TLR4 gene variants in Taiwan MGN patients by comparing them with matched controls.
MATERIALS AND METHODS

Study population
A total of 134 patients with previously renal biopsyapproved MGN and 263 healthy subjects serving as controls were recruited in Taichung Veterans General Hospital, Taiwan. Patients with malignancy, chronic infection diseases (including infections with hepatitis B and C viruses), lupus nephritis, or drug-induced secondary MGN were excluded from the study. The general data (gender, body weight, systolic/diastolic pressure, and body height) and medical information (duration of follow-up, renal failure, and herbal use, etc.) of all the patients were reviewed. Patient characteristics included demographic variables, clinical and laboratory data in the disease courses, vascular events (cardiovascular disease and peripheral vascular events), and treatment regimens as well as their responses. The study was approved by the Institutional Review Board (No. C08159) of China Medical University Hospital in adherence with the Declaration of Helsinki and all participating individuals signed an informed consent.
The selection of treatment modality, either supportive or aggressive with immunosuppressants was decided by the treating physician. The supportive therapy usually included diuretics, angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers dependening on patient symptoms. The immunosuppressive therapies were any of the following regimens: (1) prednisolone 1 mg/kg/day alone, (2) a six-month course of corticosteroids alternated with chlorambucil at dose of 0.2 mg/kg per day every other month 4, 23 or cyclophosphamide 1.5-2.0 mg/kg per day, (3) cyclosporine A (CyA, Neoral, Norvatis) 3-5 mg/kg per day with or without prednisolone.
Responses and outcomes
The responses to therapy were defined as the follows:
(1) no response, (2) partial remission: a proteinuria reduction of more than 50% or a final proteinuria between 0.2 to 2.0 g/day, and (3) complete remission: proteinuria less than 0.2 g/day. The 'progression of renal disease' was defined as a doubling of baseline serum creatinine (Cr) values or ESRD. ESRD was defined as patient requiring renal replacement therapy.
Genomic DNA extraction and determination of TLR4 polymorphisms
Genomic DNA was extracted from peripheral blood leukocytes (Genomic DNA kit, Roche). Genotypes of four SNPs (rs10983755, rs1927914, and rs10759932) representing 5 UTR A/G, 5 UTR A/G, and 5 UTR C/T polymorphism, respectively, and rs11536889 3 UTR C/G polymorphism in the TLR4 gene (Table 1) were performed using the SNP genotyping assay (Applied Biosystems Inc. (ABI), Foster City). The primers and probes to detect for SNPs were from the ABI assay on demand kit. Reactions were carried out according to the manufacturer's protocol. Briefly, PCR was performed in the presence of 2× TaqMan Universal PCR Master Mix (ABI), assay mix (Applied Biosystems) and genomic DNA (15 ng). The probe for fluorescence signal detection was from the ABI Prism 7900 Real Time PCR System.
Statistical analyses
The Hardy-Weinberg equilibrium was tested for each marker using a χ 2 -test. A χ 2 test or Fisher's exact test were used to determine statistically significant differences in allele/genotype frequencies. The haplotype combination of 4 polymorphisms in the TLR4 gene was estimated using HAPLOVIEW version 4.1 based on an accelerated EM algorithm 24 . The differences in the distribution of the haplotype frequencies between the two groups were assessed using a χ 2 -test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were obtained using logistic regressions to determine associations. All data were analysed with SPSS 15.0 and p < 0.05 was considered statistically significant. 
RESULTS
There was a statistically significant difference of the TLR4 gene rs10983755 A/G (p < 0.001) and rs1927914 A/G (p < 0.05) polymorphisms between controls and patients with MGN ( Table 2 ). The frequency of the 'AA' genotype in patients with MGN (6.0%) was higher than in the control group (4.5%). By comparing with 'GG' genotype, the OR of 'AA' was 2.03 (95% CI = 0.78-5.23). The frequency of the 'AG' genotype in patients with MGN (56.0%) was also higher than in the control group (37.0%). By comparing with the 'GG' genotype, the OR of AG was 2.33 (95% CI = 1.50-3.60). The allelic frequency of 'A' in patients with MGN (34.0%) was higher than in the control (23.0%). The OR for the 'A' allele was 1.72 (95% CI = 1.24-2.38, p = 0.001).
For the distribution of rs1927914 A/G polymorphism, the 'GG' genotype was higher in the patient's group (17.2%) than in the control (15.1%) with an OR of 1.58 (95% CI = 0.85-2.93). The frequency of the the 'AG' genotype in patients with MGN (50.0%) was also higher than in the control group (39.2%) with an OR of 1.77 (95% CI = 1.12-2.81). The allelic Data are expressed as n (%) or mean ± SD BMI = body mass index, BP = blood pressure frequency of 'G' in patients with MGN (42.2%) was higher than the control (34.7%) with an OR of 1.72 (95% CI = 1.01-1.85, p < 0.05). The distribution of rs10759932 C/T and rs11536889 C/T polymorphisms were also shown. There was no significant difference of genotype frequency between these two groups.
The characteristics of clinical parameters in TLR4 gene (rs10983755) A/G polymorphism revealed no difference except triglyceride (p = 0.024) between GG and non-GG genotype in MGN patients (Table 3) . A higher level of triglyceride was found in the non-GG group than in the GG group (245 ± 172 and 187 ± 115 mg/dl, respectively). Non-GG genotype (98.8%) had a significantly (p = 0.004) higher percentage of proteinuria than the GG genotype (85.1%). Other parameters including renal failure, mortality, vascular event, CCr, C3, C4, immunoglobulins, results of biopsy (fibrosis or intima fibroplasia), disease progression and chronic kidney disease grade did not differ for the GG and non-GG genotype of rs10983755 in the TLR4 gene.
There was also a statistically significant difference between the rs1927914 A/G polymorphism and the proteinuria parameter ( Table 4 ). The genotype of the non-AA group (97.8%) had a significantly (p = 0.011) higher ratio of proteinuria than the AA group (85.0%). No statistically significant differences of rs10759932 C/T and rs11536889 C/T polymorphisms between TT and non-TT genotypes were found in the www.scienceasia.org clinical parameters (data not shown).
In addition, compared with the haplotype frequencies between patient and control groups, the distribution of haplotype frequencies of TLR4 gene in 4 genetic variants revealed no statistical difference between MGN patients and controls (Table 5) .
DISCUSSION
MGN is a multiple factorial disease with immunologic expressions that may arise in genetically susceptible individuals 4, 9 . However, little information is available for the polymorphic gene sequences of inflammatory genes known to be involved in pathogenesis of MGN [25] [26] [27] . In this study, we focused on the variants of TLR4 which had previously been investigated for diabetic neuropathy 28 , severe virus infections 29 , cervical cancer susceptibility 30 , and chronic allograft nephropathy 31 . According to our data, we found a statistically significant association between MGN and the TLR4 gene, rs10983755 A/G, and rs1927914 A/G polymorphisms. The genetic basis of MGN is not fully understood. MGN patients show significantly lower renal expression of tumour necrosis factor (TNF-α) than patients with minimal change disease, diabetes nephropathy, IgA nephropathy, or other diseases 32 . A recent report shows that the TNF-α gene G-308A polymorphism is a risk factor for the development of MGN 33 . Other reports show no relationship between severity or progression of the disease and any of the tested single genotypes [HLA-DR3, TNF-α gene G-308A, angiotensin-converting enzyme insertion/deletion (ACE I/D), angiotensin II receptor 1 (AT1R 1166A/C), angiotensinogen (AGT M235T), and NOS (ecNOS4b/a)] 34, 35 , perhaps due to the smaller number of patients and short observation periods.
The renal function changes and the course of MGN are more strongly correlated with the degree of tubulointerstitial damage than with the extent of the glomerular lesion 36 . However, the pathogenesis of the interstitial inflammation and fibrosis is unclear. The most frequent presentation is proteinuria in the nephrotic range, with or without the other findings of the complete nephrotic syndrome. A variable percentage of cases present as asymptomatic proteinuria, with microscopic haematuria in most of the patients, but macrohaematuria is rare. Exceptionally it can appear with isolated haematuria. The renal function can be slightly altered at the time of the diagnosis in many cases, but renal failure is unusual at presentation. Furthermore, MGN may be influenced by risk factors such as microalbuminuria or hypoglycaemia. Because these risk factors were found to be distributed differently in the groups (TLR4 gene rs10983755 A/G and rs1927914 A/G) in this study, it seems that the effects of these TLR4 genotypes on MGN are related to these risk factors in these patients.
The amino acid polymorphisms determine the differences in the structure and thus the pattern recognition of the TLR4 receptor 37 . One might suggest that an abnormality in the TLR regulation might increase the susceptibility for diseases because of a reduced defence against invading pathogens 38 . Diagnosis of MGN can only be made after excluding secondary causes. Therefore, for proper diagnosis, investigations based on history, serology, and histology are equally important as a deficiency could arise at any level. MGN has a histological appearance, which could be due to factors such as heavy metal exposure, hepatitis B or C 39, 40 , Epstein-Barr virus 41 , parasites, Heli-cobacter pylori infection 42 , SLE, or even neoplastic conditions 43 . To date, no data are available concerning the function and expression of TLR4 in MGN. The pattern recognition receptor TLR4 is known to activate the proinflammatory transcription factor (NF)-κB and subsequent gene expression of NF-κB-regulated genes such as cytokines and adhesion molecules. This indicates that a TLR-4 polymorphism that prevents ligand binding and subsequent cellular signalling would result in lower NF-κB activation and subsequent NF-κB-dependent proinflammatory gene expression 44 . Hence, further studies are required to show whether the polymorphisms are associated with a reduced activation of NF-κB, cytokine expression, and expression of adhesion molecules in MGN patients.
In the present study, clinical features of 129 patients regarding vascular events (including unstable angina, coronary artery disease, ischaemic heart disease, renal artery or vein thrombosis, deep vein thrombosis and cranial vascular events) were available for review and data analysis. We observed all MGN patients had high levels of cholesterol (reference: 150-240 mg/dl) and 46% (59/129) MGN patients with vascular events problem (38% (18/47) with GG genotype at rs10983755; 50% (41/82) with Non-GG genotype at rs10983755). Comparing intergroup genotype (GG and Non-GG) gave statistically significant differences in triglycerides level for rs10983755 SNP (p = 0.024) in MGN patients. Data indicated triglycerides as 'atrisk' for vascular event development in MGN patients with Non-GG genotype. On the other hand, patients with MGN presented varied signs and symptoms, most commonly haematuria (75%), proteinuria (50%), and oedema (38%), consistent with other publications. Patients may have hypoalbuminaemia but most have hypercholesterolemia 45 . The value of proteinuria is as a marker for the MGN patients' responses to therapy.
The interpretation of our study results is limited because the patients were recruited from just one centre in Taiwan. Our results strongly suggest a significant role of TLR4 gene polymorphisms in the risk of developing MGN of Taiwan. To the best of our knowledge, this is the first report on TLR4 gene polymorphisms in MGN patients. However, the identification of TLR4 as genetic risk factors for MGN susceptibility in Taiwan may be further evaluated as prognostic markers for predictive clinical testing in MGN worldwide, especially in ethnically disparate populations. Additionally, the study lacks functional genetics, the functional activity of the two identified polymorphisms in peripheral blood lymphocytes or the expression of TLR-4 in renal biopsies of MGN patients and other glomerulopathies should be further studied. More recently, Hwang et al showed the importance of TLR4 in the pathogenesis of acute rejection in kidney transplantation, although there was no difference in transcriptional activity between wildtype and variant promoter of TLR4 46 . This means that there is no functional significance in this promoter SNPs of TLR4. The DNA variant responsible for the difference in the genetic background of MGN pathogenesis remains to be identified.
In summary, our study firstly demonstrated the different genotype distribution between normal controls and patients with MGN of the TLR4 gene. The data show that TLR4 gene may be associated with a disease clinical cause of MGN especially with respect to the clinical parameters of proteinuria and serum triglyceride levels. The TLR4 gene is one of a number of important inflammatory related genes. Our observations suggest that these polymorphisms contribute to the genetic background of MGN pathogenesis.
